457 related articles for article (PubMed ID: 33777024)
1. Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment.
Martinez MA
Front Immunol; 2021; 12():635371. PubMed ID: 33777024
[No Abstract] [Full Text] [Related]
2. Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review.
Kröker A; Tirzīte M
Respir Res; 2021 Nov; 22(1):304. PubMed ID: 34838020
[TBL] [Abstract][Full Text] [Related]
3. Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites.
El Kantar S; Nehmeh B; Saad P; Mitri G; Estephan C; Mroueh M; Akoury E; Taleb RI
Drug Discov Today; 2020 Oct; 25(10):1822-1838. PubMed ID: 32801052
[TBL] [Abstract][Full Text] [Related]
4. The challenges and opportunities of traditional Chinese medicines against COVID-19: a way out from a network perspective.
Zuo HL; Lin YC; Huang HY; Wang X; Tang Y; Hu YJ; Kong XJ; Chen QJ; Zhang YZ; Hong HC; Li J; Hu SY; Huang HD
Acta Pharmacol Sin; 2021 Jun; 42(6):845-847. PubMed ID: 33850275
[No Abstract] [Full Text] [Related]
5. Ensuring continued progress for development of COVID-19 therapeutics in children.
Noel GJ; DeBiasi RL; Crandall W; Connor EM
Pediatr Res; 2021 Dec; 90(6):1112-1114. PubMed ID: 33603214
[No Abstract] [Full Text] [Related]
6. Cutaneous lesions and COVID-19: Cystic painful lesion in a case with positive SARS-CoV-2.
Goudarzi S; Dehghani Firouzabadi F; Dehghani Firouzabadi M; Rezaei N
Dermatol Ther; 2020 Nov; 33(6):e14266. PubMed ID: 32882081
[No Abstract] [Full Text] [Related]
7. Fighting COVID-19 with Artificial Intelligence.
Monteleone S; Kellici TF; Southey M; Bodkin MJ; Heifetz A
Methods Mol Biol; 2022; 2390():103-112. PubMed ID: 34731465
[TBL] [Abstract][Full Text] [Related]
8. Alopecia areata in a patient with SARS-Cov-2 infection.
Sgubbi P; Savoia F; Calderoni O; Longo R; Stinchi C; Tabanelli M
Dermatol Ther; 2020 Nov; 33(6):e14295. PubMed ID: 32909635
[No Abstract] [Full Text] [Related]
9. Immune interventions in COVID-19: a matter of time?
Plaçais L; Richier Q; Noël N; Lacombe K; Mariette X; Hermine O
Mucosal Immunol; 2022 Feb; 15(2):198-210. PubMed ID: 34711920
[TBL] [Abstract][Full Text] [Related]
10. An EUA for bamlanivimab and etesevimab for COVID-19.
Med Lett Drugs Ther; 2021 Apr; 63(1621):49-50. PubMed ID: 33830966
[No Abstract] [Full Text] [Related]
11. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19.
Majumder J; Minko T
AAPS J; 2021 Jan; 23(1):14. PubMed ID: 33400058
[TBL] [Abstract][Full Text] [Related]
12. Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges.
Chang R; Sun WZ
Drug Discov Today; 2020 Oct; 25(10):1786-1792. PubMed ID: 32629169
[TBL] [Abstract][Full Text] [Related]
13. Isolated maculopapular eruption localized to head and neck: A cutaneous sign of COVID-19 infection.
Farabi B; Atak MF
Dermatol Ther; 2020 Nov; 33(6):e14468. PubMed ID: 33112023
[No Abstract] [Full Text] [Related]
14. Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials.
Paul SS; Biswas G
Mini Rev Med Chem; 2021; 21(9):1123-1143. PubMed ID: 33355053
[TBL] [Abstract][Full Text] [Related]
15. Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
Million M; Roussel Y; Gautret P; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106240. PubMed ID: 33408019
[No Abstract] [Full Text] [Related]
16. An EUA for sotrovimab for treatment of COVID-19.
Med Lett Drugs Ther; 2021 Jun; 63(1627):97-xx98. PubMed ID: 34181630
[No Abstract] [Full Text] [Related]
17. Drugs against SARS-CoV-2: What do we know about their mode of action?
Valle C; Martin B; Touret F; Shannon A; Canard B; Guillemot JC; Coutard B; Decroly E
Rev Med Virol; 2020 Nov; 30(6):1-10. PubMed ID: 32779326
[TBL] [Abstract][Full Text] [Related]
18. Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19.
Colson P; La Scola B; Lagier JC; Gautret P; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106238. PubMed ID: 33408030
[No Abstract] [Full Text] [Related]
19. Coronavirus disease 2019 and epidermolysis bullosa: Report of three cases.
Abdollahimajd F; Youssefian L; Pourani MR; Vahidnezhad H; Uitto J
Dermatol Ther; 2020 Nov; 33(6):e14194. PubMed ID: 32794270
[No Abstract] [Full Text] [Related]
20. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
